Frontiers in Medicine,
Год журнала:
2024,
Номер
11
Опубликована: Июль 31, 2024
Hepatocellular
carcinoma
(HCC)
is
the
most
common
primary
liver
cancer.
Surgery
has
been
major
treatment
method
for
HCC
owing
to
HCC’s
poor
sensitivity
radiotherapy
and
chemotherapy.
However,
its
effectiveness
limited
by
postoperative
tumour
recurrence
metastasis.
Systemic
therapy
applied
eliminate
residual
cells
improve
survival
of
patients
with
advanced
HCC.
Recently,
emergence
various
novel
targeted
immunotherapeutic
drugs
significantly
improved
prognosis
immunological
therapies
may
not
always
produce
complete
long-lasting
anti-tumour
responses
because
heterogeneity
drug
resistance.
Traditional
patient-derived
cell
lines
or
animal
models
are
used
investigate
resistance
mechanisms
identify
that
could
reverse
This
study
comprehensively
reviewed
established
methods
applications
in-vivo
in-vitro
further
understand
in
provide
a
model
basis
possible
individualised
therapy.
Journal of Materials Chemistry B,
Год журнала:
2024,
Номер
12(29), С. 7001 - 7019
Опубликована: Янв. 1, 2024
The
properties
of
nanomaterials
make
them
promising
and
advantageous
for
use
in
drug
delivery
systems,
but
challenges
arise
from
the
immune
system's
recognition
exogenous
nanoparticles,
leading
to
their
clearance
reduced
targeting
efficiency.
Journal of Science Advanced Materials and Devices,
Год журнала:
2024,
Номер
9(3), С. 100770 - 100770
Опубликована: Июль 23, 2024
Due
to
the
non-specific
distribution
of
drugs
in
body
and
low
concentration
at
tumor
site
traditional
chemotherapy,
there
are
challenges
associated
with
significant
side
effects
resistance.
Therefore,
a
drug
delivery
system
(DDS)
urgently
needs
be
developed
that
can
precisely
target
tumors.
Metal-organic
frameworks
(MOFs)
possess
advantageous
characteristics
derived
from
organic
inorganic
materials,
including
small
particle
size,
large
specific
surface
area,
high
loading
capacity,
adjustable
structure
pore
as
well
ease
modification.
Consequently,
MOFs
offer
unique
advantages
for
designing
active
targeting,
passive
stimulus-responsive
targeting
strategies
have
become
hot
topic
current
research
on
tumor-targeted
systems.
This
review
will
elaborate
application
systems
perspective
different
strategies.
We
hope
this
paper
provide
assistance
therapy.
Journal of Medicinal Chemistry,
Год журнала:
2024,
Номер
67(10), С. 8020 - 8042
Опубликована: Май 10, 2024
Promising
targeted
therapy
options
to
overcome
drug
resistance
and
side
effects
caused
by
platinum(II)
drugs
for
treatment
in
hepatocellular
carcinoma
are
urgently
needed.
Herein,
six
novel
multifunctional
platinum(IV)
complexes
through
linking
agents
glycyrrhetinic
acid
(GA)
were
designed
synthesized.
Among
them,
complex
20
showed
superior
antitumor
activity
against
tested
cancer
cells
including
cisplatin
than
simultaneously
displayed
good
liver-targeting
ability.
Moreover,
can
significantly
cause
DNA
damage
mitochondrial
dysfunction,
promote
reactive
oxygen
species
generation,
activate
endoplasmic
reticulum
stress,
eventually
induce
apoptosis.
Additionally,
effectively
inhibit
cell
migration
invasion
trigger
autophagy
ferroptosis
HepG-2
cells.
More
importantly,
demonstrated
stronger
tumor
inhibition
ability
or
the
combo
of
cisplatin/GA
with
almost
no
systemic
toxicity
A549
xenograft
models.
Collectively,
could
be
developed
as
a
potential
anti-HCC
agent
treatment.
Biomedicine & Pharmacotherapy,
Год журнала:
2024,
Номер
177, С. 117118 - 117118
Опубликована: Июль 14, 2024
Hepatocellular
carcinoma
(HCC)
is
one
of
the
most
prevalent
malignant
tumors
in
contemporary
era,
representing
a
significant
global
health
concern.
Early
HCC
patients
have
mild
symptoms
or
are
asymptomatic,
which
promotes
onset
and
progression
disease.
Moreover,
advanced
insensitive
to
chemotherapy,
making
traditional
clinical
treatment
unable
block
cancer
development.
Sorafenib
(SFB)
first-line
targeted
drug
for
with
anti-angiogenesis
anti-tumor
cell
proliferation
effects.
However,
efficacy
SFB
constrained
by
its
off-target
distribution,
rapid
metabolism,
multi-drug
resistance.
In
recent
years,
nanoparticles
based
on
variety
materials
been
demonstrated
enhance
targeting
therapeutic
against
HCC.
Concurrently,
advent
joint
delivery
systems
has
furnished
crucial
empirical
evidence
reversing
This
review
will
summarize
application
nanotechnology
field
over
past
five
years.
It
focus
research
progress
combined
multiple
modalities
treatment.
Medicine,
Год журнала:
2025,
Номер
104(6), С. e41415 - e41415
Опубликована: Фев. 7, 2025
Lung
cancer
is
one
of
the
most
common
malignant
tumors,
with
highest
morbidity
and
mortality
rates.
Currently,
significant
progress
has
been
made
in
treatment
lung
cancer,
which
effectively
improved
overall
prognosis
patients,
but
there
are
still
many
problems,
such
as
tumor
recurrence,
drug
resistance,
serious
complications.
With
rapid
development
nanotechnology
field
medicine,
it
breaks
through
inherent
limitations
traditional
treatments
shows
great
potential
treatment.
To
address
drawbacks
therapeutic
means,
nanodrug
delivery
systems
can
release
drugs
under
specific
conditions,
thus
realizing
tumor-targeted
delivery,
improves
antitumor
effect
drugs.
In
this
paper,
we
review
current
for
further
discuss
advantages
carriers
systems.
We
also
summarize
latest
research
nanotargeted
therapy,
problems
faced
their
clinical
translation,
look
forward
to
future
opportunities
directions.
Journal of Nanobiotechnology,
Год журнала:
2024,
Номер
22(1)
Опубликована: Апрель 24, 2024
Abstract
The
insufficient
abundance
and
weak
activity
of
tumour-infiltrating
lymphocytes
(TILs)
are
two
important
reasons
for
the
poor
efficacy
PD-1
inhibitors
in
hepatocellular
carcinoma
(HCC)
treatment.
combined
administration
tanshinone
II
A
(TSA)
astragaloside
IV
(As)
can
up-regulate
TILs
by
normalising
tumour
blood
vessels
reducing
levels
immunosuppressive
factors
respectively.
For
enhancing
antibody,
a
magnetic
metal–organic
framework
(MOF)
with
homologous
cell
membrane
(Hm)
coating
(Hm@TSA/As-MOF)
is
established
to
co-deliver
TSA&As
into
HCC
microenvironment.
Hm@TSA/As-MOF
spherical
nanoparticle
has
high
total
drug-loading
capacity
16.13
wt%.
Hm
responsiveness
provide
homologous-magnetic
dual-targeting,
which
enable
counteract
interference
posed
ascites
cells
enhance
precision
targeting
solid
tumours.
also
evade
immune
clearance
macrophages.
release
from
be
accelerated
microenvironment,
thereby
up-regulating
synergistic
antibody
against
HCC.
This
study
presents
nanoplatform
improve
HCC,
providing
novel
approach
anti-tumour
immunotherapy
clinical
practice.
Frontiers in Oncology,
Год журнала:
2025,
Номер
14
Опубликована: Янв. 6, 2025
Ankyrin
repeat
domain
27
(ANKRD27)
has
been
found
to
be
associated
with
certain
cancers.
However,
its
clinical
potential
in
pan-cancer
remains
unclear.
Public
datasets
(TCGA
and
GTEx)
were
applied
analyze
ANKRD27
expression
multiple
cancer
types
correlations
immune
scores,
checkpoint
genes,
modulatory
genes.
We
also
examined
hepatocellular
carcinoma
(HCC)
patients
using
TCGA
GSE14520
datasets.
The
upregulation
of
was
verified
via
qRT-PCR
vitro.
Based
on
TCGA-HCC,
external,
cohorts,
the
associations
between
survival
outcome
explored
Kaplan-Meier
curve.
effects
reduction
HCC
cell
growth,
movement,
invasion
evaluated
by
CCK-8,
Wound
healing,
Transwell
assays.
exhibited
aberrant
cancers
correlated
traits,
including
infiltration,
Elevated
TCGA-HCC
cohorts
confirmed
lines.
high
had
poorer
prognosis.
In
vitro,
reducing
decreased
capability
proliferation,
migration,
cells.
High
sensitivity
drugs.
displays
abnormal
levels
different
is
linked
status
cancer.
Furthermore,
may
serve
as
a
prognostic
predictor
for
HCC.
Biomaterials Advances,
Год журнала:
2025,
Номер
170, С. 214234 - 214234
Опубликована: Фев. 14, 2025
This
systematic
review
aims
to
summarize
the
development
of
erythrocyte
membrane
vesicles
(EMVs)
as
drug
delivery
carriers,
with
a
focus
on
elucidating
their
fate
in
terms
biodistribution
and
pharmacokinetics
preclinical
studies.
The
PubMed
database
was
systematically
reviewed
search
for
original
peer-reviewed
published
studies
use
EMVs
findings,
following
PRISMA
guidelines.
A
total
142
articles
matched
selection
criteria
were
included
review.
For
each
study,
parameters
extracted:
type
active
pharmaceutical
ingredient
(API)
encapsulated
into
EMVs,
EMVs-API
formulation
method
final
particle
size,
surface
modifications
targeting,
cell
lines
animal
models
used
crucial
treatment
data,
data
finally,
where
applicable,
about
circulation
time
blood
half-life.
size
did
not
vary
significantly
among
different
methods.
complete
list
is
provided.
Circulation
times
half-life
grouped
per
type.
most
commonly
type,
BALB/c
mice,
average
EMV-API
calculated
be
10.4
h,
all
cases,
up
10-fold
increase
observed
compared
that
free
API.
Surface
drastically
change
but
improve
target
tissue
accumulation.
critical
weaknesses
analysed
identified.
Key
points
future
are
provided
fill
current
knowledge
gaps
quality
publications.
